OCUL
NASDAQ · Pharmaceuticals
Ocular Therapeutix Inc
$7.14
+0.32 (+4.69%)
Financial Highlights (FY 2026)
Revenue
54.88M
Net Income
-280,903,114
Gross Margin
87.3%
Profit Margin
-511.9%
Rev Growth
+0.3%
D/E Ratio
0.11
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 87.3% | 87.3% | 60.7% | 60.7% |
| Operating Margin | -519.7% | -467.8% | 16.1% | 19.8% |
| Profit Margin | -511.9% | -486.3% | 14.8% | 14.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 54.88M | 54.72M | 384.00M | 364.41M |
| Gross Profit | 47.94M | 47.80M | 232.96M | 221.08M |
| Operating Income | -285,255,447 | -255,962,016 | 61.85M | 72.20M |
| Net Income | -280,903,114 | -252,056,632 | 56.73M | 50.92M |
| Gross Margin | 87.3% | 87.3% | 60.7% | 60.7% |
| Operating Margin | -519.7% | -467.8% | 16.1% | 19.8% |
| Profit Margin | -511.9% | -486.3% | 14.8% | 14.0% |
| Rev Growth | +0.3% | +0.3% | -3.5% | -8.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 69.40M | 69.40M | 542.51M | 619.03M |
| Total Equity | 636.67M | 636.67M | 1.53B | 1.48B |
| D/E Ratio | 0.11 | 0.11 | 0.35 | 0.42 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -280,646,004 | -265,816,255 | 95.97M | 85.28M |
| Free Cash Flow | — | — | 61.23M | 57.18M |